SCHEMBL30348692

SCHEMBL30348692

Cc1nc2ccc(-c3c[nH]c4nc(NC5CCN(C)CC5)ncc34)cc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 3/20 0.47
▸ DYRK1B Q9Y463 2/20 0.47
▸ CLK2 P49760 1/20 0.44
▸ CLK3 P49761 1/20 0.44
▸ RET P07949 1/20 0.44
▸ ROCK2 O75116 1/20 0.40
▸ BRD4 O60885 2/20 0.40
▸ MAPK8 P45983 3/20 0.40
▸ MAPK9 P45984 2/20 0.40
▸ IL2 P60568 1/20 0.40
▸ MAP4K1 Q92918 1/20 0.40
▸ MAPK10 P53779 1/20 0.40
▸ LCK P06239 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ CDK2 P24941 2/20 0.38
▸ MAPK7 Q13164 1/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ CDK4 P11802 1/20 0.38
▸ CCNB1 P14635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25158417 1.00 DYRK1A (0.47) DYRK1ADYRK1BCLK2CLK3RET
SCHEMBL25158434 0.90 CDC7 (0.42) DYRK1ADYRK1BCLK2CLK3RET
SCHEMBL30348489 0.88 DYRK1A (0.44) DYRK1ACLK2CLK3RETROCK2
SCHEMBL25158420 0.88 DYRK1A (0.44) DYRK1ACLK2CLK3RETROCK2
SCHEMBL30348557 0.87 DYRK1A (0.43) DYRK1ADYRK1BCLK2CLK3ROCK2
SCHEMBL25214569 0.87 DYRK1A (0.43) DYRK1ADYRK1BCLK2CLK3ROCK2
SCHEMBL25203199 0.86 RET (0.45) DYRK1ADYRK1BCLK2CLK3RET
SCHEMBL25157917 0.86 BRD4 (0.39) DYRK1ADYRK1BCLK2CLK3ROCK2
SCHEMBL25266090 0.86 RET (0.45) DYRK1ADYRK1BCLK2CLK3RET
SCHEMBL30348704 0.86 BRD4 (0.39) DYRK1ADYRK1BCLK2CLK3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885DYRK1B 2/4885CLK2 466/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885DYRK1B 2/4885CLK2 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback